



Financial Tear Sheet

Corporate Profile

Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Our proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Our lead programs address inflammatory diseases, genetic disorders and oncology.

Primary IR Contact

MacDougall Biomedical
Communications
Karen Sharma

Phone: 781-235-3060

E-mail:

ksharma@macbiocom.com

Recent Headlines & Events

03/09/18 - 10:48 a.m.

[Exicure, Inc. Reports Full Year 2017
Financial Results and Corporate
Progress](#)

There are currently no events scheduled.

01/31/18 - 9:38 a.m.

[Exicure to Present at BIO CEO &
Investor Conference, Immuno-Oncology
360° Summit and LEERINK Partners 7th
Annual Global Healthcare Conference](#)

01/05/18 - 11:59 a.m.

[Exicure, Inc. to Present at Biotech
Showcase 2018](#)

SEC Filings

Filing Date	Form
03/09/18	<u>10-K</u>
03/09/18	<u>8-K</u>
02/13/18	<u>S-8</u>

02/07/18

424B3

Data provided by Nasdaq. Minimum 15 minutes delayed.